Gallium Ga-68 Gozetotide Patent Expiration

Gallium Ga-68 Gozetotide is used for detecting prostate cancer lesions in men through positron emission tomography after radiolabeling with gallium-68. It was first introduced by Univ California Los Angeles in its drug Gallium Ga 68 Gozetotide on Dec 1, 2020. Other drugs containing Gallium Ga-68 Gozetotide are Illuccix, Locametz. 4 different companies have introduced drugs containing Gallium Ga-68 Gozetotide.


Gallium Ga-68 Gozetotide Patents

Given below is the list of patents protecting Gallium Ga-68 Gozetotide, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Locametz US12109277 Apparatus and method for penetrating and enlarging adjacent tissue layers Mar 09, 2036 Novartis
Illuccix US11027031 Kit for radiolabelling Jul 28, 2035 Telix
Locametz US11369590 PSMA binding ligand-linker conjugates and methods for using Aug 15, 2028 Novartis



Gallium Ga-68 Gozetotide's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List